 ROCKVILLE, MD and CHICAGO, IL, Nov. 30, 2020 GLOBE NEWSWIRE -- MacroGenics, Inc. Nasdaq: MGNX, a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that it has partnered with EVERSANA, a pioneer of next-generation commercial services to the global life sciences industry, to commercialize margetuximab in the United States, if approved. 